MedTrace Logo

Open-Label Study of Thalidomide for Chronic Prostatitis/Chronic Pelvic Pain

NCT00301405 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2013-08-05

No results posted yet for this study

Summary

To determine the efficacy of thalidomide for treatment of the Chronic Pelvic Pain Syndrome (CPPS).

Conditions

  • Chronic Prostatitis
  • Pelvic Pain

Interventions

DRUG

Thalidomide

Open label drug

Sponsors & Collaborators

  • Celgene Corporation

    collaborator INDUSTRY

  • William Beaumont Hospitals

    collaborator OTHER

  • Kenneth Peters, MD

    lead OTHER

Principal Investigators

  • Kenneth Peters, MD · William Beaumont Hospital Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-03-31
Primary Completion
2006-11-30
Completion
2006-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00301405 on ClinicalTrials.gov